These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 17211470)

  • 41. [Expression of maspin protein and correlation between maspin and P53 proteins in gastric carcinoma].
    He Y; Zhang L; Li YJ; Ye F; Jiang Y; Jin XM
    Zhonghua Yi Xue Za Zhi; 2007 Apr; 87(13):909-12. PubMed ID: 17650404
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Expression of multidrug-resistance-related proteins P-glycoprotein, glutathione-S-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma.
    Shi H; Lu D; Shu Y; Shi W; Lu S; Wang K
    Cancer Invest; 2008 May; 26(4):344-51. PubMed ID: 18443954
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Thymidine kinase and thymidylate synthetase activities in human gastric cancer].
    Kawachi Y
    Nihon Geka Gakkai Zasshi; 1993 Sep; 94(9):993-9. PubMed ID: 8246876
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Orotate phosphoribosyltransferase levels in gastric carcinoma and normal gastric mucosa - correlation with thymidylate synthase and dihydropyrimidine dehydrogenase levels and the changes after neoadjuvant chemotherapy].
    Sakurai Y; Furuta S; Sunagawa R; Tonomura S; Inaba K; Shoji M; Nakamura Y; Isogaki J; Komori Y; Uyama I; Kamoshida S; Tsutsumi Y
    Gan To Kagaku Ryoho; 2007 Oct; 34(10):1581-7. PubMed ID: 17940372
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Expression of multidrug resistance-related proteins p-glycoprotein, glutathione-s-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma.
    Shi H; Lu D; Shu Y; Shi W; Lu S; Wang K
    Hepatogastroenterology; 2008; 55(86-87):1530-6. PubMed ID: 19102336
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Inhibitory effect of somatostatin analogue octreotide on the expression of p53 and Ras in human gastric cancer].
    Tian L; Li S
    Nan Fang Yi Ke Da Xue Xue Bao; 2011 Jun; 31(7):1245-8. PubMed ID: 21764706
    [TBL] [Abstract][Full Text] [Related]  

  • 47. p53 protein overexpression as a predictor of the response to chemotherapy in gastric cancer.
    Nakata B; Chung KH; Ogawa M; Ogawa Y; Yanagawa K; Muguruma K; Inoue T; Yamashita Y; Onoda N; Maeda K; Sawada T; Sowa M
    Surg Today; 1998; 28(6):595-8. PubMed ID: 9681607
    [TBL] [Abstract][Full Text] [Related]  

  • 48. E2F1 overexpression correlates with thymidylate synthase and survivin gene expressions and tumor proliferation in non small-cell lung cancer.
    Huang CL; Liu D; Nakano J; Yokomise H; Ueno M; Kadota K; Wada H
    Clin Cancer Res; 2007 Dec; 13(23):6938-46. PubMed ID: 18056168
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Annexin XI is associated with cisplatin resistance and related to tumor recurrence in ovarian cancer patients.
    Song J; Shih IeM; Salani R; Chan DW; Zhang Z
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6842-9. PubMed ID: 17982121
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with small cell lung cancer.
    Lee HW; Han JH; Kim JH; Lee MH; Jeong SH; Kang SY; Choi JH; Oh YT; Park KJ; Hwang SC; Sheen SS; Lim HY
    Lung Cancer; 2008 Jan; 59(1):95-104. PubMed ID: 17889401
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gal-3 is stimulated by gain-of-function p53 mutations and modulates chemoresistance in anaplastic thyroid carcinomas.
    Lavra L; Ulivieri A; Rinaldo C; Dominici R; Volante M; Luciani E; Bartolazzi A; Frasca F; Soddu S; Sciacchitano S
    J Pathol; 2009 May; 218(1):66-75. PubMed ID: 19199318
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Survivin expression in gastric cancer: Association with histomorphological response to neoadjuvant therapy and prognosis.
    Vallböhmer D; Drebber U; Schneider PM; Baldus S; Bollschweiler E; Brabender J; Warnecke-Eberz U; Mönig S; Hölscher AH; Metzger R
    J Surg Oncol; 2009 Jun; 99(7):409-13. PubMed ID: 19347901
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Allelic imbalance at p53 and microsatellite instability are predictive markers for resistance to chemotherapy in gastric carcinoma.
    Yashiro M; Inoue T; Nishioka N; Matsuoka T; Boland CR; Hirakawa K
    Ann Surg Oncol; 2009 Oct; 16(10):2926-35. PubMed ID: 19597886
    [TBL] [Abstract][Full Text] [Related]  

  • 54. TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin.
    Kim JG; Sohn SK; Chae YS; Song HS; Kwon KY; Do YR; Kim MK; Lee KH; Hyun MS; Lee WS; Sohn CH; Jung JS; Kim GC; Chung HY; Yu W
    Cancer Chemother Pharmacol; 2009 Jul; 64(2):355-60. PubMed ID: 19052714
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Detection of cell-free ERCC1 and thymidylate synthase (TS) mRNA in malignant effusions and its association with anticancer drug sensitivity.
    Wang L; Liu B; Wang T; Ding Y; Qian X; Zhao Y
    Anticancer Res; 2008; 28(2A):1085-91. PubMed ID: 18507058
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunohistochemical expression of cell-cycle proteins in gastric precancerous lesions.
    Anagnostopoulos GK; Stefanou D; Arkoumani E; Karagiannis J; Paraskeva K; Chalkley L; Habilomati E; Tsianos E; Agnantis NJ
    J Gastroenterol Hepatol; 2008 Apr; 23(4):626-31. PubMed ID: 18397488
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy.
    Kim JG; Ryoo BY; Park YH; Kim BS; Kim TY; Im YH; Kang YK
    Cancer Chemother Pharmacol; 2008 Feb; 61(2):301-7. PubMed ID: 17429626
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cisplatin induces p53-dependent FLICE-like inhibitory protein ubiquitination in ovarian cancer cells.
    Abedini MR; Muller EJ; Brun J; Bergeron R; Gray DA; Tsang BK
    Cancer Res; 2008 Jun; 68(12):4511-7. PubMed ID: 18559494
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of combined administration of DPD-inhibitory oral fluoropyrimidine, S-1, plus paclitaxel on gene expressions of fluoropyrimidine metabolism-related enzymes in human gastric xenografts.
    Sakurai Y; Yoshida I; Kamoshida S; Inaba K; Isogaki J; Komori Y; Uyama I; Tsutsumi Y
    Ann Surg Oncol; 2008 Aug; 15(8):2301-9. PubMed ID: 18506536
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer.
    Lee SJ; Cho SH; Yoon JY; Hwang JE; Bae WK; Shim HJ; Chung IJ
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):159-66. PubMed ID: 19479256
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.